Peptide and compounding law · Updated
Is BPC-157 legal?
BPC-157 is not FDA-approved, has no USP monograph, is not part of any approved drug, and is not on the bulks lists that let pharmacies compound from it. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies and licensed physicians that compound BPC-157 under section 503A, on a patient-specific prescription and under the policy's conditions. That is federal enforcement discretion, not approval. It does not cover 503B outsourcing facilities, and it does not make it lawful to sell BPC-157 as a "research chemical" for people to use.
| Date | What happened | Source |
|---|---|---|
| 2018 and 2020 | BPC-157 nominated for the 503A bulks list (International Peptide Society, through LDT Health Solutions; Wells Pharmacy Network) | Regulations.gov |
| September 29, 2023 | FDA places BPC-157 in Category 2 (significant safety risks): immunogenicity, peptide impurities, and "no, or only limited, safety-related information" | FDA safety-risk page |
| April 14 and 20, 2026 | Both nominators withdraw their nominations | Regulations.gov |
| April 22, 2026 | FDA moves BPC-157 to a "nominated but withdrawn" table. It is not placed in Category 1 | FDA safety-risk page |
| July 23-24, 2026 | FDA staff propose not listing BPC-157. The Pharmacy Compounding Advisory Committee votes to recommend it, reported as 8 to 6 with one abstention | FDA briefing |
| October 30, 2026 | HHS publishes a draft enforcement-discretion policy for BPC-157 and five other peptides (epitalon, KPV, MOTS-c, Semax, TB-500), 503A compounding only, comments open two weeks | 91 FR 68526; HHS policy |
| Channel | Status |
|---|---|
| 503A pharmacy or licensed physician, patient-specific prescription, within the HHS policy's conditions | HHS does not intend to take enforcement action (draft policy) |
| 503B outsourcing facility | Not covered by the HHS policy; BPC-157 is not on the 503B list |
| Seller of "research use only" BPC-157 to consumers | Unapproved new drug when the seller's site shows human use |
| Dietary supplement | No FDA statement either way; the Defense Department says it is not a dietary ingredient (OPSS) |
| FDA-approved product | None exists |
Why BPC-157 has no ordinary legal path
A pharmacy compounding under section 503A may use a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or is on the FDA's 503A bulks list (21 U.S.C. 353a(b)(1)(A)). The FDA's July 2026 briefing put BPC-157's position plainly: "There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for BPC-157 (free base) or its acetate form, and neither is a component of an FDA-approved drug" (FDA briefing, p. 8). It is not on the 503A list or the 503B list.
That left the FDA's interim category system. BPC-157 sat in Category 2 from September 29, 2023, which meant the FDA had identified significant safety concerns and offered compounders no assurance. After both nominators withdrew in April 2026, the FDA moved BPC-157 and eleven other peptides to a "nominated but withdrawn" table on April 22, 2026, with the same safety statement still attached.
The July 2026 advisory committee
The FDA brought BPC-157 to its Pharmacy Compounding Advisory Committee on July 23 and 24, 2026 even though the nominations had been withdrawn, along with TB-500, KPV, MOTS-c, emideltide, Semax and epitalon (meeting page). FDA staff proposed listing none of them. For BPC-157, the agency evaluated only ulcerative colitis and cited poor characterization of the substance, missing safety and immunogenicity data, insufficient evidence of effectiveness, and existing approved treatments.
The committee voted the other way on six of the seven, including BPC-157, by a vote news outlets reported as 8 to 6 with one abstention. The FDA had not posted minutes on the meeting page as of November 2, 2026. A committee vote is advice; it does not put a substance on the list.
What the October 30, 2026 HHS policy does
HHS, not the FDA, issued the policy. The Federal Register notice says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A", and that the FDA's future rulemaking "may propose" adding some or all of these peptides to the 503A list (91 FR 68526). Appendix A of the policy on the HHS website lists six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Emideltide, the seventh peptide the committee reviewed, is not on it.
The policy's conditions include a patient-specific prescription; a single listed peptide per product (no blends); for BPC-157 acetate, subcutaneous, intramuscular, oral or topical forms only; bulk ingredient from an FDA-registered facility with a valid certificate of analysis; reporting serious adverse events and product-quality problems to the FDA and to the states; documented oral bioavailability for oral forms; no device packaged with the drug except an FDA-cleared syringe; and a label reading "This is a compounded drug product. Not for resale." Every other requirement of section 503A still applies.
The notice calls the policy a draft, open for comment for two weeks after October 30; the policy itself calls it an interim policy. It "does not establish any rights for any person and is not binding on HHS or the public", and HHS says it may revisit it "if, among other things, a safety signal or product quality issue arises". A citizen petition submitted October 23, 2026 asks the FDA not to allow compounding of these peptides at all.
What it does not do
- It does not approve BPC-157 or say that it is safe or effective. Compounded drugs are not FDA-approved.
- It does not cover 503B outsourcing facilities, so clinics cannot buy BPC-157 as office stock.
- It does not cover research chemicals or supplements. Selling BPC-157 labeled "for research use only" to people who will use it remains selling an unapproved new drug (21 CFR 201.128).
- It does not change state law. A pharmacy still needs its state permits and must meet its board's compounding rules.
- It does not stop the FDA or HHS from changing course. Enforcement discretion can be withdrawn.
Enforcement so far
The FDA has named BPC-157 in warning letters to compounding pharmacies in 2019 and 2020, to a supplement seller in 2020, and to an online "research purpose only" seller in 2023 (Warrior Labz letter). A Kentucky compounding pharmacy and its owner pleaded guilty in October 2020 to distributing unapproved new drugs; BPC-157 was among the drugs named in the plea agreement (DOJ, E.D. Ky.). In April 2026 a federal grand jury in Utah indicted a physician who allegedly obtained peptides from China that he knew were not FDA-approved, BPC-157 among them, and sold them to his patients (DOJ, D. Utah). An indictment is an allegation, not a finding of guilt.
The FDA's more recent research-peptide letters, in 2024 through August 2026, have focused on GLP-1 drugs, PT-141, tesamorelin and similar products rather than BPC-157. That reflects where the FDA has put its effort, not a change in the law.
North Carolina and athletes
The HHS policy is federal. North Carolina's Board of Pharmacy requires a valid prescription for a compounded drug and allows office-use compounding only as federal law permits (21 NCAC 46 .2801). A federal decision not to enforce does not change state law, and we have found no Board statement on the HHS policy as of November 2, 2026. A North Carolina clinic or pharmacy should confirm its position before it starts; see peptide law for clinics and pharmacies.
BPC-157 is on the World Anti-Doping Agency's prohibited list as a non-approved substance (S0), according to the FDA's briefing. That applies to athletes whatever HHS does.
Common questions
Is BPC-157 FDA-approved?
No. There is no FDA-approved BPC-157 product, no USP monograph, and it is not a component of any approved drug.
Can a pharmacy compound BPC-157 now?
Since October 30, 2026, HHS says it does not intend to take enforcement action against 503A pharmacies and licensed physicians that compound BPC-157 for an individual patient's prescription under the conditions of its draft policy. It is not on the bulks list, and the policy can change.
Which peptides does the HHS policy cover?
Six, listed in Appendix A of the policy: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. The policy's conditions apply to all six; for BPC-157 acetate it names subcutaneous, intramuscular, oral and topical forms.
Can my doctor prescribe BPC-157?
A prescriber may write a prescription for a compounded BPC-157 product, and a 503A pharmacy may fill it under the HHS policy's conditions. The prescriber and the pharmacy are each responsible for meeting their own board's rules.
Can a med spa keep BPC-157 in stock?
Not under the HHS policy. Office stock comes from 503B outsourcing facilities, and the policy covers only 503A compounding for individual patients. BPC-157 is not on the 503B list.
Is it legal to buy BPC-157 online as a research chemical?
Selling BPC-157 labeled "for research use only" to people who will use it is, in the FDA's view, selling an unapproved new drug. The HHS policy does not cover research chemicals.
Why did the FDA remove BPC-157 from Category 2?
Because its nominators withdrew their nominations in April 2026. The FDA moved it to a "nominated but withdrawn" table on April 22, 2026, kept its safety statement, and did not place it in Category 1.
Is BPC-157 banned for athletes?
Yes. It is on the World Anti-Doping Agency's prohibited list as a non-approved substance.
Update log
- November 2, 2026. Published. FDA lists and documents and Regulations.gov records checked October 30, 2026; the HHS policy and its Appendix A, the Justice Department releases, the Federal Register notice and the FDA meeting page checked November 2, 2026. The July 2026 vote count is as reported in the news; the FDA has not posted minutes.
Sources
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026)
- HHS, the policy with Appendix A (peptides covered) and Appendix B, hhs.gov PDF (read November 2, 2026)
- Partnership for Safe Medicines, citizen petition to the FDA (October 23, 2026)
- U.S. Attorney's Office, E.D. Ky., Nicholasville compounding pharmacy and its owner sentenced (February 24, 2021)
- U.S. Attorney's Office, D. Utah, physician indicted over misbranded drugs from China (April 1, 2026)
- Department of Defense, Operation Supplement Safety, BPC-157 (April 29, 2025)
- FDA, BPC-157 briefing document, Pharmacy Compounding Advisory Committee (July 2026)
- FDA, July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
- FDA, Certain Bulk Drug Substances That May Present Significant Safety Risks (current as of April 22, 2026)
- FDA, 503A category list (updated May 14, 2026)
- 21 U.S.C. 353a (section 503A)
- 21 CFR 201.128 (intended use)
- Withdrawal of the Wells Pharmacy Network nomination (Regulations.gov)
- FDA warning letter, Warrior Labz SARMS (June 12, 2023)
- 21 NCAC 46 .2801 (North Carolina compounding rule; Cornell LII copy)
Related
Thinking about offering BPC-157 under the HHS policy?
DPS Law advises clinics, physicians and pharmacies on North Carolina and federal compounding law. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state.